Mirum Pharmaceuticals, Inc.
MIRM
주식 순위
#3345
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
주가
$80.17
마지막 동기화: 2026-10-16
시가총액
$5.21B
변동 (1일)
-2.69%
변동 (1년)
9.03%
국가
US
거래 Mirum Pharmaceuticals, Inc. (MIRM)
카테고리
Healthcare
Mirum Pharmaceuticals, Inc. (MIRM)의 EPS
June 2026 기준 EPS TTM: $-14.56
Mirum Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-14.56입니다. 2023년 말에는 회사의 EPS가 $-4.00였으며, 이는 2022년의 EPS $-4.01와 감소입니다.
Mirum Pharmaceuticals, Inc.의 EPS 기록 (2018 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
